Immunotherapy method
A technology of immunotherapy and immunogen, applied in the direction of pharmaceutical formula, antibody medical components, allergen antigen components, etc., can solve unforeseen and complex immune system problems
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0183] Example 1 Selective tolerance of TH2 immunity
[0184] Specific pathogen-free C57BL / 6J and BALB / c mice were purchased from the Animal Resource Center (Murdoch University, Western Australia) and housed at the Telethon Institute for Child Health Research under barrier conditions. Animals were maintained in a temperature and lighting controlled environment and housed on low-dust bedding. Animals were fed acidified water and an autoclaved diet of OVA-free food pellets. Late-gestational females were monitored daily at 9:00 AM and 5:00 PM for date of delivery. The day of birth is assigned as day 0. Newborn animals were defined as animals born 24 hours after birth. Adult mice aged 6-8 weeks can be used. All animal experiments were approved by the Institute's Animal Ethics and Experimentation Committee, which adheres to regulations set by the National Health and Medical Research Council of Australia.
[0185] Adult mice were fed 3 x 1 mg OVA (Grade V; Sigma, MO, USA) dis...
Embodiment 2
[0187] Example 2 Selective tolerance of TH1 immunity
[0188] Adult mice were fed 3 x 1 mg of OVA or PBS for 3 consecutive days as described in Example 1 above. However, after 4 weeks, the mice were challenged intraperitoneally with 100 μg of OVA in complete Freund's adjuvant. Again, the draining lymph node cells were stimulated with 1 mg / ml OVA in vitro for 11 days, and the cytokines in the culture supernatant were measured according to the description in Example 1. figure 2 Selective tolerance of TH1 immunity was shown, as OVA-fed mice produced reduced in vitro production of the TH1 cytokine IFN-γ after challenge with OVA in complete Freund's adjuvant, concomitantly with production of the TH2 cytokine IL-5 increase as shown.
Embodiment 3
[0189] Example 3 Non-selective tolerance of overall OVA-specific TH cell immunity
[0190] Adult mice were fed with 3 x 1 mg OVA or PBS for 3 consecutive days as shown in Examples 1 and 2 above. However, after 4 weeks, the mice were challenged intraperitoneally with 100 μg of soluble OVA in PBS. Again, draining lymph node cells after 11 days were stimulated in vitro with 1 mg / ml OVA, and cytokines in the culture supernatants were assayed as described above. image 3 A non-selective tolerance of overall OVA-specific TH cell immunity was demonstrated, as shown by a parallel decrease in the in vitro production of IL-5 and IFN-g in animals following challenge with unadjuvanted soluble OVA.
PUM
Login to View More Abstract
Description
Claims
Application Information
Login to View More